Genetically modified mice and engraftment

Patent metadata

Field	Value
Publication number	US-9301509-B2
Application number	US-201213617448-A
Country	US
Kind code	B2
Filing date	Sep 14, 2012
Priority date	Oct 6, 2009
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

First claim

We claim:

1. A genetically modified mouse, comprising a replacement of a mouse thrombopoietin (TPO) gene with a human TPO gene at both alleles of a mouse TPO gene locus,
wherein the mouse does not express mouse TPO,
wherein the mouse is immunocompromised for a mouse immune system,
wherein the mouse is engrafted with human hematopoietic cells, and
wherein the mouse comprises a statistically significant increase in human CD45+ hematopoietic cells in the bone marrow relative to a human hematopoietic cell-engrafted mouse expressing mouse TPO.

2. The mouse according to claim 1 , wherein the mouse comprises a human hemato-lymphoid system.

3. The mouse according to claim 2 , wherein the human hemato-lymphoid system comprises human cells selected from the group consisting of hematopoietic stem cells, hematopoietic CD34+ cells, myeloid precursor cells, myeloid cells, dendritic cells, monocytes, granulocytes, neutrophils, mast cells, lymphocytes, and platelets.

4. The mouse according to claim 2 , wherein the mouse is null for a RAG gene and null for the mouse interleukin 2 receptor gamma (IL-2Rγ) gene.

5. A method of producing a mouse comprising a human hemato-lymphoid system, the method comprising:
engrafting a population of cells that comprises human hematopoietic cells into a immunodeficient genetically modified mouse, wherein the genetically modified mouse comprises a replacement of a mouse thrombopoietin (TPO) gene with a human TPO gene at both alleles of a mouse TPO gene locus, wherein the mouse does not express mouse TPO, and
wherein the engrafted mouse comprises a statistically significant increase in human CD45+ hematopoietic cells in the bone marrow relative to a human hematopoietic cell-engrafted mouse expressing mouse TPO.

6. The method according to claim 5 , wherein said population of cells comprises a population of human umbilical cord blood cells or human fetal liver cells.

7. The method according to claim 5 , wherein said population of cells comprises human CD34+ cells.

8. The method according to claim 5 , wherein the human hemato-lymphoid system comprises human cells selected from the group consisting of hematopoietic stem cells, myeloid precursor cells, myeloid cells, dendritic cells, monocytes, granulocytes, neutrophils, mast cells, lymphocytes, and platelets.

9. The method according to claim 5 , further comprising:
irradiating the genetically modified mouse prior to the engrafting.

10. The method according to claim 5 , wherein the mouse is null for a RAG gene and null for the mouse interleukin 2 receptor gamma (IL-2Rγ) gene.

11. The method according to claim 5 , further comprising assessing the human hemato-lymphoid system for human hematopoietic cells,
wherein the human hemato-lymphoid system comprises an enhanced percent of human hematopoietic cells relative to percent of human hematopoietic cells in an engrafted mouse that lacks a humanization of a TPO gene.

12. The method according to claim 11 , wherein the assessing comprises detecting myeloid cells,
wherein the human hemato-lymphoid system comprises an enhanced percent of myeloid cells relative to percent of myeloid cells in an engrafted mouse that lacks a human TPO gene.

13. The method according to claim 11 , wherein the assessing comprises detecting granulocytes,
wherein the human hemato-lymphoid system comprises an enhanced percent of granulocytes relative to percent of granulocytes in an engrafted mouse that lacks a human TPO gene.

14. The method according to claim 11 , wherein the assessing comprises detecting hematopoietic stem cells, wherein the population comprises an enhanced percent of hematopoietic stem cells relative to percent of hematopoietic stem cells in an engrafted mouse that lacks a human TPO gene.

15. A mouse comprising a humanized cellular immune system, wherein the mouse is null for a RAG gene and null for the mouse interleukin 2 receptor gamma (IL-2Rγ) gene and comprises:
a replacement of a mouse thrombopoietin (TPO) gene with a human TPO gene at both alleles of a mouse TPO gene locus, wherein the mouse does not express mouse TPO; and
a human hemato-lymphoid system,
wherein the mouse comprises a statistically significant increase in human CD45+ hematopoietic cells in the bone marrow relative to a mouse comprising a human hemato-lymphoid system and expressing mouse TPO.

16. The mouse according to claim 15 , wherein the mouse comprises a S. typhi infection.

17. The mouse according to claim 16 , wherein the S. typhi infection is a systemic S. typhi infection.

18. The mouse according to claim 15 , comprising a Mycobacterium tuberculosis infection.

Assignees

• Stevens Sean
• Murphy Andrew J
• Flavell Richard
• Eynon Elizabeth
• Galan Jorge
• Willinger Tim
• Manz Markus
• Rongvaux Anthony
• Yancopoulos George D
• Regeneron Pharma
• Univ Yale
• Inst Res Biomedicine Irb

Inventors

• Stevens Sean
• Murphy Andrew J
• Flavell Richard
• Eynon Elizabeth
• Galan Jorge
• Willinger Tim
• Manz Markus
• Rongvaux Anthony
• Yancopoulos George D

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N9/00

  Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00) · CPC title

• A01K67/0278 Primary

  Knock-in vertebrates, e.g. humanised vertebrates · CPC title

• A01K2267/03

  Animal model, e.g. for test or diseases · CPC title

• A01K2267/0387

  Animal model for diseases of the immune system · CPC title